ALTEOGEN Inc Total Assets
ALTEOGEN Inc total assets. Based on the latest financial reports, ALTEOGEN Inc (196170) holds total assets worth ₩739.91 Billion KRW (≈ $501.43 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALTEOGEN Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Total Assets of ALTEOGEN Inc (2014–2025)
Total assets of ALTEOGEN Inc from 2014 to 2025. This chart illustrates how ALTEOGEN Inc's total assets have evolved over time, based on quarterly financial data. See ALTEOGEN Inc (196170) share price today for real-time trading data and today's change.
ALTEOGEN Inc - Asset Composition Analysis
ALTEOGEN Inc Total Assets Breakdown (December 2025)
ALTEOGEN Inc total assets breakdown as of December 2025. ALTEOGEN Inc's total assets of ₩739.91 Billion consist of 68.8% current assets and 31.2% non-current assets. Explore ALTEOGEN Inc (196170) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 9.5% |
| Accounts Receivable | ₩4.81 Billion | 0.7% |
| Inventory | ₩6.53 Billion | 0.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩120.12 Billion | 17.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how ALTEOGEN Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ALTEOGEN Inc's current assets represent 68.8% of total assets in 2025, an increase from 66.4% in 2014.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2025, down from 22.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 17.2% of total assets.
ALTEOGEN Inc Competitors by Total Assets
Key competitors of ALTEOGEN Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
ALTEOGEN Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.76 | 1.64 | 19.50 |
| Quick Ratio | 2.73 | 1.63 | 19.41 |
| Cash Ratio | 0.00 | 0.00 | 1.57 |
| Working Capital | ₩333.02 Billion | ₩158.60 Billion | ₩209.66 Billion |
ALTEOGEN Inc - Advanced Valuation Insights
This section examines the relationship between ALTEOGEN Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 36.24 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 70.8% |
| Total Assets | ₩698.74 Billion |
| Market Capitalization | $9.97 Billion USD |
Valuation Analysis
Below Book Valuation: The market values ALTEOGEN Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ALTEOGEN Inc's assets grew by 70.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ALTEOGEN Inc (2014–2025)
The table below shows the annual total assets of ALTEOGEN Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩698.74 Billion ≈ $473.53 Million |
+70.84% |
| 2024-12-31 | ₩409.01 Billion ≈ $277.18 Million |
+59.71% |
| 2023-12-31 | ₩256.10 Billion ≈ $173.56 Million |
+4.32% |
| 2022-12-31 | ₩245.49 Billion ≈ $166.37 Million |
-5.70% |
| 2021-12-31 | ₩260.34 Billion ≈ $176.43 Million |
+63.52% |
| 2020-12-31 | ₩159.21 Billion ≈ $107.89 Million |
+85.17% |
| 2019-12-31 | ₩85.98 Billion ≈ $58.27 Million |
+20.45% |
| 2018-12-31 | ₩71.38 Billion ≈ $48.37 Million |
+65.95% |
| 2017-12-31 | ₩43.01 Billion ≈ $29.15 Million |
-10.29% |
| 2016-12-31 | ₩47.95 Billion ≈ $32.49 Million |
+21.74% |
| 2015-12-31 | ₩39.39 Billion ≈ $26.69 Million |
+3.76% |
| 2014-12-31 | ₩37.96 Billion ≈ $25.72 Million |
-- |
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more